PMID- 27663309
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 9
IP  - 1
DP  - 2016 Sep 23
TI  - Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell 
      transplantation in China: a multicenter prospective observational study.
PG  - 97
LID - 97
AB  - BACKGROUND: Antifungal prophylaxis is currently regarded as the gold standard in 
      situations with allo-genetic hematopoietic stem cell transplantation (allo-HSCT). 
      However, the epidemiological information regarding prophylaxis of invasive fungal 
      diseases (IFDs) is not clear in China. METHODS: We report the first large-scale 
      (1053 patients) observational study of the prophylaxis and management of IFDs 
      among patients with allo-HSCT in China. RESULTS: The incidence rates of IFD after 
      primary antifungal prophylaxis (PAP), secondary antifungal prophylaxis (SAP), and 
      non-prophylaxis were 22.7 vs. 38.6 vs. 68.6 %, respectively (P = 0.0000). The 
      median time from transplantation to IFD was 45 days in PAP patients, 18 days in 
      SAP patients, and 12 days in non-prophylaxis patients. Aspergillus spp. 
      represents the most common type of fungal infection. Independent risk factors for 
      IFD in allo-HSCT patients with PAP were age, having human leukocyte antigen 
      (HLA)-haploidentical or matched unrelated donor, decreased albumin levels, and 
      the use of itraconazole as the prophylactic antifungal agent. Among SAP 
      transplant recipients, there was no significant risk factor for IFDs. The 
      incidence rates of overall survival (OS) in the PAP, SAP, and no prophylaxis 
      groups were 85.07, 78.80, and 74.82, respectively (P = 0.01). CONCLUSIONS: This 
      observational study indicates that prophylaxis of IFD is helpful to reduce the 
      incidence of IFDs and improve the OS of patients after allo-HSCT.
FAU - Gao, Lei
AU  - Gao L
AD  - Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
FAU - Sun, Yuqian
AU  - Sun Y
AD  - Peking University Institute of Hematology, Peking University People's Hospital, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      100044, China.
FAU - Meng, Fanyi
AU  - Meng F
AD  - Nanfang Hospital, Nanfang Medical University, Guangzhou, China.
FAU - Han, Mingzhe
AU  - Han M
AD  - Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical 
      Sciences, Tianjin, China.
FAU - Huang, He
AU  - Huang H
AD  - The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, 
      China.
FAU - Wu, Depei
AU  - Wu D
AD  - The First Affiliated Hospital of Soochow University, Suzhou, China.
FAU - Yu, Li
AU  - Yu L
AD  - Chinese PLA General Hospital (301 Hospital), Beijing, China.
FAU - Ren, Hanyun
AU  - Ren H
AD  - The First Hospital of Peking University, Beijing, China.
FAU - Huang, Xiaojun
AU  - Huang X
AD  - Peking University Institute of Hematology, Peking University People's Hospital, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      100044, China.
FAU - Zhang, Xi
AU  - Zhang X
AD  - Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. 
      zhangxxi@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20160923
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
PMC - PMC5035465
OTO - NOTNLM
OT  - Allogenetic
OT  - China
OT  - Invasive fungal diseases
OT  - Prophylaxis
OT  - Stem cell
OT  - Transplantation
EDAT- 2016/09/25 06:00
MHDA- 2016/09/25 06:00
PMCR- 2016/09/23
CRDT- 2016/09/25 06:00
PHST- 2016/03/19 00:00 [received]
PHST- 2016/08/24 00:00 [accepted]
PHST- 2016/09/25 06:00 [entrez]
PHST- 2016/09/25 06:00 [pubmed]
PHST- 2016/09/25 06:00 [medline]
PHST- 2016/09/23 00:00 [pmc-release]
AID - 10.1186/s13045-016-0305-y [pii]
AID - 305 [pii]
AID - 10.1186/s13045-016-0305-y [doi]
PST - epublish
SO  - J Hematol Oncol. 2016 Sep 23;9(1):97. doi: 10.1186/s13045-016-0305-y.